1. TUmor-volume to breast-volume RAtio for improving COSmetic results in breast cancer patients (TURACOS); a randomized controlled trial.
- Author
-
Lagendijk, M., Vos, E. L., Koning, A. H. J., Hunink, M. G. M., Pignol, J. P., Corten, E. M. L., de Monye, C., van Deurzen, C. H. M., van Dam, J. H., Vrijland, W. W., Contant, C. M. E., Verhoef, C., van Lankeren, W., and Koppert, L. B.
- Subjects
BREAST surgery ,BREAST cancer ,QUALITY of life ,CANCER patients ,TUMORS ,ANTHROPOMETRY ,BREAST ,MAMMOGRAMS ,BREAST tumors ,COMPARATIVE studies ,DECISION making ,MATHEMATICAL models ,RESEARCH methodology ,MEDICAL cooperation ,QUESTIONNAIRES ,RESEARCH ,STATISTICAL sampling ,ULTRASONIC imaging ,THEORY ,LUMPECTOMY ,EVALUATION research ,RANDOMIZED controlled trials - Abstract
Background: Cosmetic result following breast conserving surgery (BCS) for cancer influences quality of life and psychosocial functioning in breast cancer patients. A preoperative prediction of expected cosmetic result following BCS is not (yet) standard clinical practice and therefore the choice for either mastectomy or BCS is still subjective. Recently, we showed that tumour volume to breast volume ratio as well as tumour location in the breast are independent predictors of superior cosmetic result following BCS. Implementation of a prediction model including both factors, has not been studied in a prospective manner. This study aims to improve cosmetic outcome by implementation of a prediction model in the treatment decision making for breast cancer patients opting for BCS.Methods/design: Multicentre, single-blinded, randomized controlled trial comparing standard preoperative work-up to a preoperative work-up with addition of the prediction model. Tumour volume to breast volume ratio and tumour location in the breast will be used to predict cosmetic outcome in invasive breast cancer patients opting for BCS. Three dimensional (3D)-ultrasonography will be used to measure the tumour volume to breast volume ratio needed for the prediction model. Sample size was estimated based on a 14% improvement in incidence of superior cosmetic result one year after BCS (71% in the control group versus 85% in the intervention group). Primarily cosmetic outcome will be evaluated by a 6-member independent panel. Secondary endpoints include; (1) patient reported outcome measured by BREAST-Q, EORTC-QLQ-C30/BR23 and EQ-5D-5 L (2) cosmetic outcome as assessed through the BCCT.core software, (3) radiation-induced reaction (4) surgical treatment performed, (5) pathological result and (6) cost-effectiveness. Follow-up data will be collected for 3 years after surgery or finishing radiotherapy.Discussion: This randomized controlled trial examines the value of a preoperative prediction model for the treatment-decision making. It aims for a superior cosmetic result in breast cancer patients opting for BCS. We expect improvement of patients' quality of life and psychosocial functioning in a cost-effective way.Trial Registration: Prospectively registered, February 17th 2015, at 'Nederlands Trialregister - NTR4997 '. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF